Results 121 to 130 of about 289,373 (313)

Layer-by-layer biofabrication of coronary covered stents with clickable elastin-like recombinamers [PDF]

, 2019
Producción CientíficaCoronary artery disease is the leading cause of death around the world. Endovascular stenting is the preferred treatment option to restore blood flow in the coronary arteries due to the lower perioperative morbidity when compared ...
Fernández Colino, Alicia, Jockenhoevel, Stefan, Mela, Petra, Moreira, Ricardo, Rodríguez Cabello, José Carlos, Rütten, Stephan, Schmitz-Rode, Thomas, Wolf, Frederic   +7 more
core   +2 more sources

FPR2 Agonism Attenuates Restenosis by Mitigating Neointimal Hyperplasia via ELOVL6

The FASEB Journal, Volume 39, Issue 17, 15 September 2025.
Restenosis after revascularization in lower extremity arterial disease remains a major unmet need. We demonstrate reduced formylpeptide receptor 2 (FPR2) expression in human restenotic arteries and demonstrate that FPR2 deficiency exacerbates neointimal hyperplasia.
Qian Zhang, Yuqin Zha, Xiaoting Wang, Peishen Zhao, Owen L. Woodman, Mi Zhou, Yuguo Chen, Xiaojun Zhou, Cheng Xue Qin   +8 more
wiley   +1 more source

Treatment of atherosclerotic renovascular hypertension: review of observational studies and a meta-analysis of randomized clinical trials. [PDF]

, 2015
open9Atherosclerotic renal artery stenosis can cause ischaemic nephropathy and arterial hypertension. We herein review the observational and randomized clinical trials (RCTs) comparing medical and endovascular treatment for control of hypertension and ...
Caielli, P, Calò, Frigo, Anna Chiara, Maiolino, G, Miotto, Diego, Pengo, Mf, Rossi, Gianpaolo, Rossitto, G, Seccia, Teresa Maria   +8 more
core   +1 more source

Red Blood Cell Membrane Lipidomics: Potential Biomarkers Detecting Method for Plasma Volume Overload and Major Adverse Cardiovascular Events in Chronic Heart Failure Patients

Advanced Science, Volume 12, Issue 33, September 4, 2025.
A novel RBC indicator, ESI, is better than the traditional RBC indicators and is associated with CHF prevalence and in‐hospital death. RBC membrane lipidomics, Cer 18:0;O2/16:0, and LPE 18:0, are associated with plasma volume overload and MACE in CHF patients, but these plasma lipids could not.
Lin Zhang, Xiangqin Ou, Jingyi Lin, Xiaofei Luo, Jiashun Zhou, Xingyue Zhou, Peihua Zhao, Li Liu, Ziran Zhao, Ying Zhou, Guanwei Fan, Lifeng Han, Xiumei Gao   +12 more
wiley   +1 more source

The application and efficacy of stent place for Budd-Chiari syndrome

Journal of Interventional Medicine, 2018
: Objective To evaluate the application value and efficacy on stent place for Budd-Chiari syndrome (BCS).Methods From January 1990 to May 2017, 2228 patients with BCS were admitted to our institution. The mean age was 43.3 years.
Maoheng Zu, Hao Xu, Yuming Gu, Qingqiao Zhang, Ning Wei, Wei Xu, Yanfeng Cui   +6 more
doaj   +1 more source

Angiotensin-converting enzyme insertion/deletion polymorphism does not influence the restenosis rate after coronary stent implantation [PDF]

, 2002
Background. Experimental studies have shown an activation of the angiotensin-converting enzyme (ACE) system as a response to endothelial injury. Recent publications have elucidated the hypothesis that the ACE gene polymorphism may influence the level of ...
de Jaegere, Peter, Ferrari, Markus, Figulla, Hans R., Grip, Lars, Hausmann, Dirk, Koschyk, Dietmar H., Mudra, Harald, Rieber, Johannes, Rothman, Martin, Schächinger, Volker, Voudris, Vassilis   +10 more
core   +1 more source

Application of the Neuroform Atlas Stent for Intracranial Stenting of Symptomatic Intracranial Atherosclerotic Stenosis: A Multi‐Center Retrospective Study

Brain and Behavior, Volume 15, Issue 9, September 2025.
Intracranial stenting with the Neuroform Atlas stent is a potentially safe and effective treatment for symptomatic intracranial atherosclerotic stenosis (sICAS). It demonstrates a statistically significant difference in the caliber of the target artery before and after treatment as well as significantly improves the cerebral ischemic symptoms of ...
Weicheng Peng, Haiyang Ma, Shuaibin Lu, Xinli Xiang, Rui Zhao, Sheng Xu, Xupeng Peng, Yuhua Jiang, Zhiqiang Hu, Feng Guan   +9 more
wiley   +1 more source

Stent Underexpansion Is an Underestimated Cause of Intrastent Restenosis: Insights From RESTO Registry

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Despite improvement in devices, in‐stent restenosis remains a frequent and challenging complication of percutaneous coronary interventions. Methods and Results The RESTO (Morphological Parameters of In‐Stent Restenosis Assessed and Identified ...
Géraud Souteyrand, Thomas Mouyen, Benjamin Honton, Aurélien Mulliez, Benoit Lattuca, Jean‐Guillaume Dilinger, Sébastien Levesque, Grégoire Range, Nicolas Combaret, Stéphanie Marliere, Ouarda Lamallem, Marine Quillot, Edouard Gerbaud, Pascal Motreff, Nicolas Amabile   +14 more
doaj   +1 more source

Design and testing of hydrophobic core/hydrophilic shell nano/micro particles for drug-eluting stent coating [PDF]

, 2018
In this study, we designed a novel drug-eluting coating for vascular implants consisting of a core coating of the anti-proliferative drug docetaxel (DTX) and a shell coating of the platelet glycoprotein IIb/IIIa receptor monoclonal antibody SZ-21.
A Arsiwala, A Bierhalz, A Tan, AW Heldman, B Almería, B O’brien, B O’Brien, C Stettler, CJ Pan, CJ Sweeney, CL Song, D Sun, DM Saylor, E Boersma, E Camenzind, ES Park, ES Thian, F Danhier, GY An, H Zhang, HG Wang, J Kanzer, J Riegger, J Yang, J Zhang, JB Slee, JJ Wykrzykowska, JM Lee, JV Natarajan, K Kolandaivelu, KH Bønaa, KS Lim, M Gawaz, M Zamani, M Zamani, MK Dong, MP Skinner, MT Ali, PS Douglas, PW Erruys, RH Müller, RK Aggarwal, RL Wilensky, S Freiberg, S Garg, S Hossfeld, S Jang, S Lee, S Mcginty, S Meng, S Puricel, S Yasuda, SJ Liu, T Inoue, T Nakano, TM Ko, U Baber, X Ma, X Wu, X Xi, Y Cao, YH Lee, Z Yang   +62 more
core   +1 more source

Cerebral Venous Thrombosis:Current Status and Challenges

Brain and Behavior, Volume 15, Issue 9, September 2025.
Our review introduces treatment strategies for short‐term, long‐term, and permanent CVT risk factors, focusing on anticoagulant selection and treatment duration. We also discuss the current status of endovascular therapy for CVT, noting that it remains a challenge due to limited evidence, and more research is needed to optimize this approach.
Wenbo Zuo, Shengcai Chen, Jiashuo Lin, Yan Wan, Fei Cao, Bo Hu   +5 more
wiley   +1 more source